Universities are really great for many things. They are even really great at commercializing some kinds of technologies. But they are not great for all things, even all things related to bio or tech transfer. Sometimes crazy bets are the only way breakthroughs happen, and generally academia cultivates incremental more than transformational.
I started my company because I wanted to make affordable medical devices. The incentive systems for both med device companies and university commercialization offices are almost completely misaligned with building a business model that works for affordable medical devices.
So I went the entrepreneurial route.
Being in academic research is not the same thing as building a company. They're not the same skill sets, or even the same language. Lots of academics become technical advisers to startups built around their research. That's not the same thing as building a company. YC is about building a company.
I wrote about being a med device company in YC here: http://bit.ly/1LlmZjk, but I think really what I was writing about was being a researcher learning to build a startup.
When it comes to research, particularly in academia, it's much farther from market. This makes it much easier to expound on the broad possibilities. News headlines have a bad habit of doing this (think fusion and carbon nano-tubes).
University projects are incredibly valuable, but only the rare exception produces something commercially viable much less supported and marketed enough to be relevant to consumers. Even in CS, an academic field with disproportionately strong industry ties, projects like this a rare exception (see how venerated Spark is); it's even rarer in other fields.
This is a different sort of work than raw R&D, but it's still difficult and relevant—just in a different way. I completely sympathize with not being interested in it, but that says more about you (and often me) than it does about YC.
If anything, the role YC plays is actually more important in biotech than in software because creating, deploying, marketing and supporting a software project is an easier problem with more existing support outside of YC. Software takes less resources, has less risks and has more buy-in from funding sources and other parts of the community than biotech. (At least, and especially, in SV.)
But, unless you're excited by an accessible version of something specific, none of this is going to be particularly relevant to you. Not only is this perfectly fine, but it bodes remembering for people in the startup community who tend to get so enamored with and immersed in what they're doing that they forget that it is not universal.
Disclaimer, my company Pembient is in the first class.
I share your intuition, I really do. I even said similar things in grad school (and still do, sometimes). But the reality is that:
1. These are not supposed to be projects, they are supposed to be companies creating products. The gulf between "Nature paper" and "something someone will buy" is incredibly long and arduous. Plus, these are VC-backed, meaning there's an expectation of timeline (short) and return (high). These aren't "take $20m from darpa and engage in another four years of R&D" type endeavors. So while they might look trivial scientifically (although I do not think that they do), they have to be working sooner rather than later.
2. "Better versions" is also a tough thing to assess. The people involved matter a lot -- thus even technically superior solutions from very smart people might still not be "better versions". I know many grad students who are much more knowledgable than some of the top data scientists, who nonetheless would fall on their faces if they tried to do a data science startup. Similar for life sciences and biotech.
I think the people who poo-poo academia are largely setting up strawmen -- even Peter Thiel (whose first VC firm, Founders Fund, backed both of my startups) admits that there's a substantial role for government and academic activity in enabling long-term technical innovation.
As biologists, we know just how hard it is to make _anything_ work in this space. Most new drugs fail, most clinical trials fail, most pathways end up being hard to target, etc. etc. Often building a company in the biotech space is like trying to build a microprocessor company where we're still not entirely sure "how the silicon works".
The challenge for YC and other VCs is to identify technologies that are "almost there", and help turn them into companies and products. That's very hard, and I'm not really even sure that we (as academics) are any good at it either.
Will some of them fail? Sure. Will some of them leave the startup scene and maybe go back and do a postdoc or work for an industrial research lab or do another startup, much wiser? Of course. But that hardly seems like a horrible outcome, especially if the scientists learn a lot along the way.
Could you point to a few of the University projects you're referring to? I think we'd especially want to know if they require similar levels of investment, since cheap long-shot approaches compliment, rather than are made obsolete by, expensive traditional approaches. (If you think cheaper approaches are hopeless, maybe you could expand.)
Medical device innovation is broken. Companies developing devices like ours are taking 10 years and $100M to see revenue, and most people in the industry consider this time and cost inevitable. For that reason, investment in the space has plummeted. ROIs suck. The thing is though that it's not inevitable. The space is ripe for smarter and more efficient ways to bring products to market. This process innovation is not coming from academia, nor will it ever. Academics just doesn't think that way, and they're categorically not good at commercialization. This new thinking is coming from independent startups that embrace a hacker mentality and reject conventional wisdom. As we all know, that's very similar to the ethos of YC.
Stanford Biodesign has a stellar track record of producing medtech winners, and that's because its process works. The advice we've heard from the YC partners in the program has aligned very well with the advice we heard from the top forward-thinking entrepreneurs in the industry at Biodesign. They get it. YC partners may not understand the intricacies of healthcare as well as industry veterans, but it doesn't need to. They understand how to build a great company regardless of vertical. YC brings in top founders from industry, who already have the necessary expertise and connections, and encourages them to think big and think differently. I don't see how that's not a winning formula. Yes, healthcare is different, but it's similar to other typical YC verticals in more ways than you think.
Haploid genetics[1] is just one example of a technology that is doing real, far reaching stuff in human genetics (sorry, SNPs). There's numerous companies being developed from discoveries using this technology.
I love YC (and huge props to you personally for all the amazing things you've contributed, I'm very honored to be speaking with you), but in talking to many colleagues, the money involved $100K or the hype machine involved in YC just doesn't move the needle in biology. So, you're unlikely to get any real players interested.
What I've noticed with the latest YC biotech start-ups is they tend to be much more focused on ideas that don't require a huge amount of capital (diagnostic platforms, biofuels, etc).
While everyone might poo-poo academia, it would take little effort to find 100s of projects at universities across the world that are better versions of these projects.
As much as YC dominates software applications, they are woefully inferior in biotech/biomedical applications.